Dr Reddys Laboratories Ltd management interview: Dr Reddy’s के Q2 Results पर कंपनी के CFO MV Narasimham से खास चर्चा! | Earnings Season
CNBC Awaaz, 2026-10-26. Video: https://www.youtube.com/watch?v=GtgW-Eh4i2k
- North America growth: Excluding last year’s lenalidomide sales, the base business delivered healthy double-digit growth, mainly from volumes and new products.
- Generics and API: The businesses declined this quarter because customers did not take some API volumes. Management expects API growth momentum to return in coming quarters.
- India market: India grew 17%, driven by volume, new products, and price. Management expects to continue growing a few basis points higher than the market.
- Emerging markets: Growth was 24% this quarter, and management expects momentum to continue across emerging markets.
- Consumer health: The acquired nicotine replacement therapy business is performing better than envisaged, with EBITDA growth above expectations. The reported decline versus last year reflects a change in sales model and gross-to-net accounting, with no impact on the bottom line, which remains healthy.